This article is mainly intended for trainees and specialists who are interested in the management of severe asthma. It aims to inform readers about the updated ERS/ATS recommendations for management of severe asthma, specifically on the topics of biologics, macrolides and long-acting muscarinic antagonists.It also provides guidance on utilisation of available biomarkers in selecting advanced therapies in severe asthma.
No takes yet. Share an insight, caveat, or question.
Khurana et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: